(Q30354497)

20 June 2017

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. (English)

1 reference

20 June 2017

phase I clinical trial

0 references

0 references

1 reference

1 reference

3

Odile Launay

1 reference

20 June 2017

Jean-Louis Bresson

1

1 reference

20 June 2017

Christian Perronne

2

1 reference

20 June 2017

Catherine Gerdil

4

1 reference

20 June 2017

Melanie Saville

5

1 reference

20 June 2017

John Wood

6

1 reference

20 June 2017

Katja Höschler

7

1 reference

20 June 2017

Maria C Zambon

8

1 reference

20 June 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

20 June 2017

1 reference

20 June 2017

367

1 reference

20 June 2017

1657-1664

1 reference

20 June 2017

9523

1 reference

Probable person-to-person transmission of avian influenza A (H5N1)

20 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968656-X

7 January 2021

Evolution of H5N1 avian influenza viruses in Asia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968656-X

7 January 2021

Development and evaluation of influenza pandemic vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968656-X

7 January 2021

Selection of influenza vaccine strains and developing pandemic vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968656-X

7 January 2021

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968656-X

7 January 2021

Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968656-X

7 January 2021

Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968656-X

7 January 2021

Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968656-X

7 January 2021

Confronting the avian influenza threat: vaccine development for a potential pandemic.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968656-X

7 January 2021

Measurement of antibodies to avian influenza virus A(H7N7) in humans by hemagglutination inhibition test

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968656-X

7 January 2021

Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968656-X

7 January 2021

A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968656-X

7 January 2021

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968656-X

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968656-X

7 January 2021

10.1016/S0140-6736(06)68656-X

Identifiers

DOI

1 reference

20 June 2017

1 reference